Onze vlaggenschip liposomale PEA-supplementen zijn superieur
in termen van absorptie en effectiviteit.
SINDOLEO for soothe support
Our flagship liposomal PEA product SINDOLEO is superior in terms of absorption and effectiveness due to our proprietary formulation process and liposome technology.
What is PEA?
Palmitoylethanolamide (PEA) is an endogenous lipid present in various mammalian tissues including the brain, liver, eyes and muscles. It is produced from membrane phospholipids and exerts a variety of functions, many of which are related to inflammation and pain signalling . Alterations in the levels of PEA are associated with chronic inflammation  and pain disorders [3,4,5] underlining its importance in these processes. PEA is a fat-soluble (insoluble) molecule that is poorly absorbed and rapidly cleared by our body, which severely limits its therapeutic use. Upon oral intake of a typical dose of its conventional powdered form, very little PEA will enter the blood circulation and reach the target sites in the human body.
PEA and pain reduction
A substantial number of preclinical and clinical studies have demonstrated that PEA administration can relieve pain (analgesia). Two meta-analyses of these studies both concluded that PEA treatment was indeed associated with significant pain reduction. Efficacy is reported in lower back pain, Carpal Tunnel Syndrome and pelvic pain [6,7]. More recent clinical studies confirm the analgesic efficacy of PEA in the treatment of patients with bladder pain syndrome , chronic pelvic pain , chronic orofacial pain , (chronic) lower back pain [11-14], Carpal Tunnel Syndrome , knee osteoarthritis , diabetes  and pain after back or spine surgery .
Several different mechanisms of action have been suggested to explain the analgesic effects of PEA. Firstly, PEA can modulate the activity of the endocannabinoid system, which plays a key role in the experience of pain . PEA does not directly bind to cannabinoid receptors but modulates their activity indirectly by preserving the natural agonists of these receptors [20,21]. Secondly, PEA reduces inflammation in the peripheral and central nervous system, which also leads to chronic pain relief [22-24].
Limitations of current PEA products
Due to its lipophilic nature and high melting point, PEA is barely soluble in water and other aqueous solvents . Its tendency to form crystalline precipitates in almost every solubilization attempt, points at the difficulty also the body faces in absorbing the compound from orally administered formulations. Little is reported concerning the bioavailability of PEA in humans, but it seems to be extremely low with only a short-lived presence in blood after oral intake [26, 27]. Attempts have been made to improve the bioavailability of crystalline PEA by reducing its particle size, allegedly leading to a stronger reduction of inflammation and tissue damage in rats . Micronized formulations of PEA are already used to treat patients with pain and inflammatory diseases and have been shown to be safe .
SINDOLEO is a technologically-superior liposomal PEA version of standard PEA products that have poor efficacy due to inadequate absorption and cellular utilization. SINDOLEO, liposomal PEA, is designed in a way that achieves complete molecular dispersion of PEA among the phospholipids in liposomes, so that the PEA molecules are immediately and fully available for intestinal uptake without the need to first dissolve out of the crystalline deposits. This way, better delivery leading to higher tissue concentrations at the target areas in the body are foreseen, leading to stronger efficacy compared to non-liposomal PEA products.
With SINDOLEO we provide you a therapeutic, bioavailable PEA that allows your body to better utilize its numerous benefits that are being studied and documented by many scientists all over the world.
“Our liposomal vitamins and other nutraceuticals are available as raw materials, capsules, tablets, liquids and many other tailored solutions. “
Liposoma Nutraceuticals; experts in liposomes
LIPOSOMA manufactures branded and white label liposomal supplements.
Our high-end liposomal nutraceuticals are guaranteed by the academic qualifications of our team and its commitment to scientific excellence.
Our liposome technology offers many advantages for nutritional supplement producers, the food sector and consumers. Our liposomal vitamins and other nutraceuticals are available as raw materials, capsules, tablets, liquids and many other tailored solutions.
Would you like to learn more? Give us a call on 0031 20 237 36 00
 Iannotti, A., Di Marzo, V., Petrosino, S. (2016). Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. Progress in Lipid Research 62:107-128.
 De Filippis, D., d’Amico, A., Cipriano, M., Petrosino, S., Orlando, P., Di Marzo, V., Iuvone, T., Iuvone, T. (2010). Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. Pharmacological Research 61(4):321–328. doi:10.1016/j.phrs.2009.11.005
 Ghafouri N, Ghafouri B, Larsson B, Stensson N, Fowler CJ, Gerdle B. (2013). Palmitoylethanolamide and stearoylethanolamide levels in the interstitium of the trapezius muscle of women with chronic widespread pain and chronic neck-shoulder pain correlate with pain intensity and sensitivity. Pain 154(9):1649-1658.
 Stensson N, Ghafouri B, Gerdle B, Ghafouri N. Alterations of anti-inflammatory lipids in plasma from women with chronic widespread pain—a case–control study. Lipids Health Dis.
 Stensson N, Ghafouri N, Ernberg M, et al. The relationship of endocannabinoidome lipid mediators with pain and psychological stress in women with fibromyalgia: a case–control study. J Pain. 2018;19(11):1318-1328.
 Artukoglu, B.B., Beyer, C., Zuloff-Shani, A., Brener, E., Bloch, M. (2017). Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis. Pain Physician 20(5):353-362.
 Paladini, A., Fusco, M., Cenacchi, T., Schievano, C., Piroli, A., Varrassi, G. (2016). Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain: A Pooled Data Meta-analysis. Pain Physician 19(2):11-24.
 Cervigni, M., Nasta, L., Schievano, C., Lampropoulou, N., Ostardo, E. (2019). Micronized Palmitoylethanolamide-Polydatin Reduces the Painful Symptomatology in Patients with Interstitial Cystitis/Bladder Pain Syndrome. BioMed Research International:9828397. doi: 10.1155/2019/9828397
 Stochino Loi, E., Pontis, A., Cofelice, V., Pirarba, S., Fais, M.F., Daniilidis, A., Melis, I., Paoletti A.M., Angioni, S. (2019). Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide/polydatin on chronic pelvic pain and quality of life in endometriosis patients: An open-label pilot study. International Journal of Women’s Health 11:443-449.
 Alshelh, Z., Mills, E.P., Kosanovic, D., Di Pietro, F., Macey, P.M., Vickers, E.R., Henderson, L.A. (2019). Effects of the glial modulator palmitoylethanolamide on chronic pain intensity and brain function. Journal of Pain Research 12:2427-2439. doi: 10.2147/JPR.S209657.
 Chirchiglia, D., Paventi, S., Seminara, P., Cione, E., Gallelli, L. (2018). N-palmitoyl ethanol amide pharmacological treatment in patients with nonsurgical lumbar radiculopathy. Journal of Clinical Pharmacology 58(6):733-739.
 Cruccu, G., Stefano, G.D., Marchettini, P., Truini, A. (2019). Micronized Palmitoylethanolamide: A Post Hoc Analysis of a Controlled Study in Patients with Low Back Pain – Sciatica. CNS & Neurological Disorders – Drug Targets 18(6):491-495.
 Passavanti, M.B., Fiore, M., Sansone, P., Aurilio, C., Pota, V., Barbarisi, M., Fierro, D., Pace, M.C. (2017). The beneficial use of ultramicronized palmitoylethanolamide as add-on therapy to Tapentadol in the treatment of low back pain: a pilot study comparing prospective and retrospective observational arms. BMC Anesthesiology 17(1):171. doi: 10.1186/s12871-017-0461-9.
 Scaturro, D., Asaro, C., Lauricella, L., Tomasello, S., Varrassi, G., Letizia Mauro G. (2019). Combination of Rehabilitative Therapy with Ultramicronized Palmitoylethanolamide for Chronic Low Back Pain: An Observational Study. Pain and Therapy. doi: 10.1007/s40122-019-00140-9. [Epub ahead of print]
 Evangelista, M., Cilli., De Vitis, R., Militerno, A., Fanfani, F. (2018). Ultra-micronized Palmitoylethanolamide Effects on Sleep-wake Rhythm and Neuropathic Pain Phenotypes in Patients with Carpal Tunnel Syndrome: An Open-label, Randomized Controlled Study. CNS & Neurological Disorders – Drug Targets 17(4):291-298. doi: 10.2174/1871527317666180420143830.
 Steels, E., Venkatesh, R., Steels, E., Vitetta, G., Vitetta, L. (2019). A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology 27(3):475-485.
 Semprini R, Martorana A, Ragonese M, Motta C. (2018). Observational clinical and nerve conduction study on effects of a nutraceutical combination on painful diabetic distal symmetric sensory-motor neuropathy in patients with diabetes type 1 and type 2. Minerva
 Paladini, A., Varrassi, G., Bentivegna, G., Carletti, S., Piroli, A., Coaccioli, S. (2017). Palmitoylethanolamide in the treatment of failed back surgery syndrome. Pain Research and Treatment 2017:1486010.
 Woodhams, S.G., Chapman, V., Finn, D.P., Hohmann, A.G., Neugebauer, V. (2017). The cannabinoid system and pain. Neuropharmacology 124:105-120. doi: 10.1016/j.neuropharm.2017.06.015.
 Di Marzo, V., Melck, D., Orlando, P., Bisogno, T., Zagoory, O., Bifulco, M., Vogel, Z., De Petrocellis, L. (2001). Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. The Biochemical Journal 358:249–255.
 Petrosino, S., Schiano Moriello, A., Cerrato, S., Fusco, M., Puigdemont, A., De Petrocellis, L. Di Marzo, V. (2016). The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoylglycerol and potentiates its actions at transient receptor potential vanilloid type-1 channels. British Journal of Pharmacology 173:1154–1162.
 Couch, D., Tasker, C., Theophilidou, E., Lund, J.N., O’Sullivan, S.E. (2017). Cannabidiol and palmitoylethanolamide are anti-inflammatory in the acutely inflamed human colon. Clinical Science (London, England) 131(21):2611-2626. doi: 10.1042/CS20171288.
 Huh, Y., Ji, R.R., Chen, G. (2017). Neuroinflammation, Bone Marrow Stem Cells, and Chronic Pain. Frontiers in Immunology 21;8;1014. doi: 10.3389/fimmu.2017.01014.
 Ji, R.R., Chamessian, A., Zhang, Y.Q. (2016). Pain regulation by non-neuronal cells and inflammation. Science 354(6312):572-577.
 Lambert, D. M., Vandevoorde, S., Diependaele, G., Govaerts, S. J., and Robert, A. R. (2001). Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia 42, 321–327. doi: 10.1046/j.1528-1157.2001.41499.x
 Petrosino, S., Schiano Moriello, A., Cerrato, S., Fusco, M., Puigdemont, A., De Petrocellis, L. Di Marzo, V. (2016). The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoylglycerol and potentiates its actions at transient receptor potential vanilloid type-1 channels. British Journal of Pharmacology 173, 1154–1162.
 Gabrielsson, L., Mattson, S. & Fowler, C.J. (2016). Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. British Journal of Clinical Pharmacology 82, 932-942.
 Petrosino, S., Cordaro, M., Verde, R., Schiano Moriello, A., Marcolongo, G., Schievano, C., Siracusa, R., Piscitelli, F., Peritore, A.F., Crupi, R., Impellizzeri, D., Esposito, E., Cuzzocrea, S., Di Marzo, V. (2018). Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect. Frontiers in Pharmacology 9, 249. doi: 10.3389/fphar.2018.00249.